Stop TB Partnership

Stop TB Partnership
Name	Stop TB Partnership
Formation	1998
Type	Public–private partnership
Headquarters	Geneva, Switzerland
Region served	Global
Leader title	Executive Director
Parent organization	World Health Organization

Stop TB Partnership Stop TB Partnership is a global public–private partnership launched to accelerate the elimination of tuberculosis through coordinated action among international organizations, national programs, and civil society. It brings together actors from multilateral institutions, national ministries, philanthropic foundations, academic centers, private industry, and affected communities to implement strategies, mobilize resources, and influence policy on tuberculosis control. Operating from Geneva, the Partnership interfaces with technical agencies, financing mechanisms, research networks, and advocacy platforms to align global efforts toward targets set by World Health Organization strategies and the United Nations Sustainable Development Goals.

History

The Partnership was created following a call to action at the World Health Assembly and the World Health Organization's recognition of a renewed global TB crisis in the late 1990s, building on earlier cooperative efforts such as the DOTS strategy and initiatives by Global Fund to Fight AIDS, Tuberculosis and Malaria, Médecins Sans Frontières, and national tuberculosis programs like those of India, South Africa, and China. Early stewardship involved technical input from research institutions including the Centers for Disease Control and Prevention and the London School of Hygiene & Tropical Medicine, and funding discussions with philanthropic actors such as the Bill & Melinda Gates Foundation. Throughout the 2000s and 2010s, Stop TB Partnership aligned with major global moments—UN High-Level Meeting on TB, 2018, successive WHO End TB Strategy milestones, and financing rounds at the Global Fund—shaping operational priorities for drug-resistant TB and key populations in settings like Eastern Europe, Sub-Saharan Africa, and Southeast Asia.

Structure and Governance

The governance architecture combines a Secretariat hosted in Geneva, an Executive Committee, and multiple working groups that include technical partners such as International Union Against Tuberculosis and Lung Disease and UNICEF. Advisory bodies draw representatives from national tuberculosis programs (e.g., Brazil Ministry of Health, Russia Ministry of Health), civil society consortia like the Treatment Action Group, and research networks such as the European Centre for Disease Prevention and Control. Funding oversight intersects with trust fund mechanisms linked to the World Bank and coordination with United Nations Development Programme offices in high-burden countries. Decision-making processes are informed by normative guidance from WHO and by stakeholder consultations that have involved delegations to forums like the World Health Assembly and technical review panels convened with partners including Gavi, the Vaccine Alliance.

Programs and Initiatives

Operational portfolios include case-finding and treatment scale-up, latent TB management, and drug-resistant TB response, executed through programmatic platforms such as the Global Drug Facility and the TB Research Movement. Key initiatives have connected with clinical trial networks at Oxford University Clinical Research Unit, diagnostics consortia involving Cepheid and Foundation for Innovative New Diagnostics, and implementation science partnerships with institutions like Johns Hopkins University and Columbia University. Campaigns addressing community engagement and stigma have partnered with networks such as the Global Network of People Living with HIV and regional bodies like the African Union. Emergency response efforts have coordinated with the United Nations Office for the Coordination of Humanitarian Affairs in humanitarian settings, while multisectoral accountability frameworks have been promoted in line with UN General Assembly resolutions.

Funding and Partnerships

Financing combines contributions from bilateral donors (for example, ministries from United States, United Kingdom, Germany, and Japan), philanthropic grants from foundations including Wellcome Trust and Bill & Melinda Gates Foundation, and procurement partnerships with suppliers and manufacturers across India and South Korea. The Partnership works closely with the Global Fund for program financing and with the World Bank on health systems investments. Private-sector collaborations have involved pharmaceutical firms, diagnostics companies, and supply-chain partners, while research funding has been coordinated with agencies such as National Institutes of Health and the European Commission. Country-level resource mobilization frequently engages national finance ministries and development banks like the Asian Development Bank.

Advocacy and Policy Influence

Stop TB Partnership has been active in shaping global policy through advocacy at forums such as the UN High-Level Meeting on TB, 2018, the World Health Assembly, and regional bodies like the Pan American Health Organization. Policy outputs often reflect consensus work with WHO guidelines, the Global Fund strategic plans, and civil society coalitions including the Global TB Caucus. The Partnership has promoted targets within the End TB Strategy and supported national strategic plans in high-burden countries such as India, Indonesia, and Nigeria. Advocacy campaigns have linked with high-profile health diplomacy platforms, engaging heads of state, parliamentarians, and international financiers to elevate TB on national and multilateral agendas.

Impact and Criticism

The Partnership contributed to mobilizing scaled access to diagnostics, medicines, and programmatic guidance, evidenced by expanded procurement through mechanisms akin to the Global Drug Facility and increased inclusion of TB in global health financing dialogues with the Global Fund and UN bodies. It fostered research linkages among institutions such as London School of Hygiene & Tropical Medicine and University of Cape Town, and supported civil society engagement in countries including Pakistan and Philippines. Criticisms have focused on the challenges of translating global coordination into consistent country-level implementation, debates about prioritization between biomedical interventions versus social determinants, and concerns about reliance on donor-driven funding models similar to critiques leveled at multilateral initiatives like the Global Fund and Gavi, the Vaccine Alliance. Evaluations have urged stronger integration with national health systems, predictable financing, and more equitable involvement of affected communities and national research institutions in decision-making.

Category:Public–private partnerships Category:Tuberculosis organizations Category:Global health organizations